Subscribe to our Email Alerts
Neuren Pharmaceuticals
  • Home
  • About Us
    • Company Overview
    • Company Values
    • Board of Directors
    • Management
    • Corporate Directory
  • Products
    • DAYBUE™ (trofinetide)
  • Pipeline
    • Pipeline
    • Trofinetide
      • Rett Syndrome
      • Fragile X Syndrome
    • NNZ-2591
      • Phelan-McDermid Syndrome
      • Angelman Syndrome
      • Pitt Hopkins Syndrome
      • Prader-Willi Syndrome
  • Science
    • Science Behind Neuren's Products
    • Scientific Presentations
    • Publications
  • Investors
    • Investor Dashboard
    • Share Price Information
    • ASX Announcements
    • Annual and Interim Reports
    • Investor Presentations
    • Corporate Governance
    • Analyst Coverage
    • Shareholder Services
  • News & Media
    • Media
  • Contact
    • Contact Us
    • Email Alerts

News & Media

 

Home > News & Media > Media
  • Media

Media

Filter by Year:2023 2022 2021 
2-Jul-2021
Peak TV interview 2 July 2021
12-Jan-2021
Neuren Pharmaceuticals receives EC Orphan designations for drug candidate NNZ-2591
19-Nov-2020
Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial
4-Mar-2020
Neuren Pharmaceuticals secures Rare Pediatric Disease designation for trofinetide to treat Rett Syndrome
5-Dec-2017
Neuren Pharmaceuticals gets green light for a patent in the U.S.
29-Jun-2017
Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials
22-Mar-2017
Neuren Pharmaceuticals drug shows promise in treating Rett syndrome
19-Mar-2017
Neuren Pharmaceuticals granted ASX trading halt pending trial update
25-Aug-2016
Neuren Pharmaceuticals Ltd advancing clinical trial for Rett syndrome
27-Jun-2016
Neuren Pharmaceuticals Ltd progresses New Drug Application for Rett syndrome
  • Previous 
  • 1
  • 2
  • 3
  •  Next

Quick Links

Contact Us

Neuren Pharmaceuticals Limited
Suite 201, 697 Burke Road
Camberwell, VIC 3124
Australia

Phone: +61 (3) 9092 0480
Email: enquiries@neurenpharma.com

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Neuren Pharmaceuticals
Site Map Privacy Search
Site by